Revolade approved for treatment of aplastic anaemia

Revolade (eltrombopag) is the first drug to be licensed in the UK for use in patients with acquired severe aplastic anaemia (SAA) who are either refractory to prior immunosuppressive therapy or heavily pretreated and unsuitable for haematopoietic stem cell transplantation (HSCT).

Further information
View Revolade drug record
Summary of Product Characteristics
Manufacturer: Novartis

The current standard of care for SAA includes immunosuppressive therapy or HSCT. Approximately 40% of patients unresponsive to initial immunosuppressive therapy die from infection or bleeding within five years of their diagnosis. 

Revolade is also indicated in chronic immune thrombocytopenic purpura and in thrombocytopenia in patients with hepatitis C.